Channel Partnerships as a Pre-M&A Strategy in HealthTech: A Strategic Playbook for European and US Markets

Nelson Advisors
1 hour ago
13 min read

The healthcare technology (HealthTech) sector has transitioned from a phase of greenfield venture formation to one characterised by rapid platform consolidation. Driven by post-pandemic market corrections, rising operational costs, and regulatory evolution, strategic corporate buyers and private equity sponsors are executing aggressive platform strategies and buy-and-build consolidation programs.

Globally, mergers and acquisitions (M&A) reached USD $4.6 Trillion, representing a 49% increase from prior lacklustre periods and marking the most active year for dealmaking since the 2021 market peak. Within this transaction wave, overall healthcare M&A deal value escalated by more than 60%, highlighted by a powerful return of "mega-deals" valued in excess of USD $10 Billion.

This macro-consolidation occurs at a time when enterprise buyers, such as health systems, insurers and large physician networks, are suffering from severe "point solution fatigue". Exhausted by managing hundreds of disparate software vendors, these buyers are actively consolidating their technology stacks. This procurement shift has erected significant commercial barriers for early-stage HealthTech companies attempting direct-to-enterprise sales motions.

To overcome these commercial bottlenecks, market-leading organisations are leveraging strategic channel partnerships as a pre-M&A mechanism. These alliances allow corporate acquirers to validate commercial viability, technical capability and cultural fit prior to committing capital to a formal transaction, while providing venture-backed targets with an efficient route to market.

The Strategic Ecosystem: Sub-Sectors and Platform Integration

The modern HealthTech ecosystem comprises a diverse range of sub-sectors, each requiring specialised commercial and integration strategies. At the core of the M&A advisory landscape are key segments such as mobile health (mHealth), electronic health and medical records (EHR/EMR), wearable devices, telehealth, telemedicine, over-the-counter (OTC) products, nutrition and retail pharmacies.

Historically, healthcare organisations procured highly specialised point solutions from a fragmented array of vendors, resulting in siloed, non-integrated technology environments that were difficult and expensive to maintain. To resolve these maintenance challenges, the industry shifted toward monolithic, single-vendor EMRs. While these monolithic databases succeeded in standardising clinical workflow documentation, they proved highly inflexible in supporting analytical use cases and hosting external applications.

In response to this rigidity, the digital health market has experienced a resurgence of integrated, "best-of-breed" point solutions. This architectural revival is facilitated by open, scalable analytics infrastructures, such as the Health Catalyst Data Operating System (DOS™), which aggregate and normalise data from proprietary source systems. By decoupling the data aggregation layer from the application layer, these open systems allow specialised point solutions to scale rapidly across the enterprise.

For a pre-M&A strategy, this shift is critical: strategic corporate buyers prioritise targets whose software can integrate into open-platform architectures. This technical alignment ensures that after a transaction closes, the target's software can be scaled across the parent company's client base without requiring expensive database restructuring.

The Pre-M&A Playbook: Timing, Structure and Revenue Dynamics

Deploying a channel partnership strategy as a precursor to a transaction requires balancing timing, commercial structure and financial incentives. Initiating partnership negotiations too early can expose an immature startup to product drift, where a powerful partner’s preferences redirect the startup's product roadmap. Conversely, waiting too long can lead to missed market opportunities and higher customer acquisition costs.

Timing and Commercial Execution

Startups vary widely in when they initiate channel relationships:

Ciitizen engaged with patient advocacy groups as marketing and lead-generation channels before its product was fully mature, leveraging early feedback to shape its development.
Cedar deferred its channel motion, exploring opportunities in its second year but waiting until its fourth year to sign its first major contract, ensuring its direct-sales playbook was repeatable before handoff.
Ginger established a highly structured partnership with navigation platform Accolade to rapidly scale its mental health services.

Enterprise sales cycles are long and complex. Data indicates that HealthTech companies utilising a significant channel motion decreased their average sales cycle by 25%. In contrast, organisations relying entirely on direct-sales motions experienced a 10% increase in their average sales cycle over the same period, illustrating the impact of partner-led distribution. These efficiencies are why 27% of surveyed healthcare founders cite reducing customer acquisition costs as a primary driver for launching channel partnerships.

Partnership Structural Models

To align incentives before a transaction, companies structure their commercial relationships across three primary models, mapped to specific phases of the customer acquisition funnel:

Partnership Category	Operational Mechanism	Strategic Value to Pre-M&A Pipeline
Marketing Partners	Focus on top-of-funnel lead generation, referring qualified prospects to the target.	Validates initial market demand and measures product interest within the partner's client base.
Co-Sale Partners	Involve direct collaboration between the partner’s sales force and the target’s reps to co-sell.	Builds operational rapport and tests the cultural and technical alignment of both sales teams.
Contracting Partners	Rely on the partner's existing contracting vehicles to ease procurement and billing.	Minimizes enterprise procurement friction and demonstrates that the software can scale through existing vendor contracts.

Financial Alignment and Revenue Models

For a channel partnership to succeed, the financial structure must protect the target's operating margins while providing the partner with sufficient incentive to actively promote the product. While fee-for-service or fixed commissions are used, revenue-sharing agreements are the most common financial structure in healthcare channel partnerships :

Revenue Model	Operational Mechanism	Alignment Incentive
Revenue Sharing	The channel partner receives a percentage of the total contract value of the closed deal.	High; directly ties the partner's financial return to the target's top-line growth.
Referral Fees	The target pays a one-time, fixed cash fee to the partner for every qualified lead that signs.	Moderate; encourages lead volume but does not incentivise long-term customer success.
Flat Deal Closure Fees	The partner receives a pre-negotiated flat payment upon the execution of a customer contract.	Moderate; rewards closing deals but does not account for variations in deal size or duration.
Commissions	Sales reps are paid a direct, variable percentage based on meeting specific sales quotas.	High for individual reps; drives direct sales engagement.

Operational Realities and the Enablement Gap

While the strategic benefits of channel partnerships are clear, operational execution is often difficult. Data shows that while 64% of surveyed companies report that channel partners contribute to their annual revenues, only 35% have effective partner coaching and development strategies in place. This disparity represents an enablement gap that often stalls promising HealthTech innovations in perpetual pilot phases.

The most significant operational challenge identified by sales teams in the field is a lack of product and brand awareness.Larger partners often have broad product catalogs, and their sales reps may default to selling familiar, high-volume products rather than learning to pitch a complex, new HealthTech solution.

To overcome this, targets must invest in structured partner enablement. This includes dedicating full-time staff to partner operations, integrating shared CRM systems to track leads, and simplifying complex clinical value propositions into repeatable sales playbooks.

Cloud Marketplaces: Leveraging Hyperscaler Distribution

Cloud marketplaces have emerged as highly efficient channel partners for enterprise HealthTech software. These platforms, operated by hyper scalers such as Amazon Web Services (AWS), Microsoft Azure and Google Cloud Platform (GCP), allow healthcare organizations to procure software using pre-allocated cloud spend.

However, cloud marketplace execution requires a distinct strategy :

Sector and Buyer Persona Alignment: HealthTech companies must align their marketplace choices with their primary buyer personas. For example, cybersecurity or infrastructure-focused HealthTech systems prioritize the AWS marketplace because of its strong relationships with hospital CIOs and CISOs. Conversely, application software providers targeting administrative and financial operations prioritise Microsoft Azure, leveraging Microsoft’s deep relationships with CFO and revenue-cycle executives.
Operational Readiness: Hyperscaler marketplaces impose complex billing and reporting requirements. HealthTech targets must prepare operationally by dedicating staff to manage marketplace research, billing systems, and custom CRM workflows. This ensures the target can accurately track whether a customer was partner-sourced or partner-involved.
Venture Capital Lever: Startups often struggle to capture the attention of large cloud providers. Leveraging strategic venture capital connections can help clear a direct path to marketplace enablement, helping early-stage companies build relationships with hyperscaler partner representatives.

Comparative Geographic Landscapes: US vs. Europe

The path from partnership to M&A is shaped by the regulatory and structural differences between the US and European healthcare markets.

The United States: Rapid Commercial Scaling and Algorithmic Moats

The US healthcare market is characterized by a high degree of private payer concentration, large integrated delivery networks (IDNs), and a focus on reducing administrative costs. Consequently, US channel partnerships often prioritise commercial speed, customer acquisition cost (CAC) reduction and rapid data integration.

The primary pre-M&A driver in the US is the creation of "algorithmic moats." US strategic acquirers look for digital health targets that can integrate clinical data, behavioural tracking, and medical hardware into a unified, automated solution.

These acquisitions are often structured to capture the high-value chronic disease market, where automating clinical recommendations and tracking patient behaviors can defend a buyer's core hardware margins.

Europe: Multi-Local Nuances, CDMO Roll-ups and Regulatory Enforcers

The European HealthTech M&A landscape is highly active, with a strong focus on digital health, artificial intelligence, and data-driven solutions. However, Europe’s fragmented, state-funded healthcare systems require a localised approach to channel partnerships, where startups must often partner with local distributors or national insurers to navigate country-specific reimbursement policies.

Furthermore, European private equity sponsors rely heavily on buy-and-build strategies, rolling up fragmented medical device manufacturers and Contract Development and Manufacturing Organisations (CDMOs) to build regional scale.

From a regulatory perspective, European transactions require compliance with the General Data Protection Regulation (GDPR) and the European Union Medical Device Regulation (EU MDR). Due diligence teams must verify that any target company handling patient data or manufacturing connected medical hardware has maintained compliant audit trails and safety reporting standards.

Europe is also seeing increased antitrust scrutiny of below-threshold transactions. Historically, small HealthTech acquisitions escaped antitrust review because their transaction values fell below standard filing thresholds. However, regulatory bodies are increasingly utilising abuse-of-dominance frameworks to review and sanction acquisitions deemed to have anticompetitive, market-foreclosing objectives.

A prime example is the French Competition Authority's (FCA) November 2025 ruling against dominant online medical booking platform Doctolib. The FCA fined Doctolib EUR 4,665,000 for abusing its dominant position by enforcing restrictive exclusivity and tying clauses on healthcare professionals.

Significantly, the FCA retroactively sanctioned Doctolib’s 2018 acquisition of its chief competitor, MonDocteur. This was the first time a regulator sanctioned a non-notifiable transaction based on the European Court of Justice’s Towercast precedent, which allows national watchdogs to review acquisitions if they are shown to prevent the emergence of a viable competitor.

Case Studies: Partnership-Led Acquisitions

These historical cases illustrate how structured commercial partnerships can evolve into successful cross-border M&A transactions.

Case Study 1: Roche and mySugr (Austria, Germany and USA)

The acquisition of Austrian digital diabetes developer mySugr by Swiss diagnostics giant Roche in June 2017 is a prime example of a partnership-to-M&A pathway.

Evolution of the Relationship

The relationship began in 2014 as a commercial partnership, driven by Roche's desire to pair its physical diagnostics hardware with a user-friendly digital interface. mySugr had built a mobile diabetes logbook app that integrated gamification such as a "diabetes monster" companion to improve daily compliance.

In 2015, the relationship deepened when the Roche Venture Fund co-led mySugr's USD $4.8 Million Series B financing round alongside iSeed Ventures. This venture investment aligned corporate incentives and provided Roche with board-level visibility into the startup's growth and technical development.

In 2016, the companies executed a major product integration, syncing Roche’s Bluetooth-enabled Accu-Chek Connect blood glucose meter directly into the mySugr app. This integration automated blood sugar logging for users.

The commercial partnership was validated by strong real-world clinical data: a cohort study of 440 diabetic patients using the integrated system demonstrated a 20% reduction in average blood glucose levels and a 1.3% drop in HbA1c over six months.

Transaction Execution and Integration

With clear evidence of clinical and commercial success, Roche acquired 100% of mySugr’s shares in June 2017. Post-acquisition, Roche chose to preserve mySugr's corporate autonomy, maintaining it as a separate legal entity.

Critically, mySugr maintained its open-platform business model, continuing to sync with competing hardware from manufacturers such as Medtronic and Abbott. This structure protected mySugr’s agile culture while allowing Roche to transition from selling low-margin hardware to delivering high-margin, bundled services.

This strategy was demonstrated in Germany, where insurer VKB launched a comprehensive digital coaching and supply bundle including the mySugr Pro app, unlimited test strips, and Roche's Accu-Chek Guide meter.

Case Study 2: Medtronic and Companion Medical (USA)

In August 2020, Medtronic announced the acquisition of San Diego-based Companion Medical, the developer of the InPen smart insulin pen system.

Algorithmic Consolidation

While much of the digital diabetes market focused on insulin pumps, a massive cohort of patients continued to rely on multiple daily injections (MDIs). Medtronic's acquisition of Companion Medical was designed to capture this MDI segment by adding the InPen hardware and app to Medtronic's diabetes ecosystem.

Companion Medical’s journey was backed by strategic industry capital. In 2015, the startup secured strategic backing from pharmaceutical leader Eli Lilly and Company, which was developing connected insulin delivery options.

This strategic backing allowed Companion Medical to navigate the regulatory process and secure FDA 510(k) clearance for its bolus dose calculator, making it the first cleared smart pen system on the US market.

Medtronic’s acquisition of Companion Medical was the final piece of an intentional, data-driven acquisition strategy:

By integrating these acquired assets, Medtronic built a comprehensive digital platform capable of delivering proactive, personalized dosing recommendations across both pump and injection users.

Case Study 3: ResMed and Propeller Health (USA and Europe)

In January 2019, ResMed completed the USD $225 Million acquisition of Madison, Wisconsin-based Propeller Health, a pioneer in respiratory digital therapeutics.

Preserving Strategic Neutrality

Propeller Health developed proprietary sensors that attach to standard asthma and COPD inhalers, pairing them with an app to track medication adherence and predict respiratory flares. Prior to its acquisition, Propeller had built a robust partner network with pharmaceutical manufacturers (such as Novartis) and retail pharmacy chains (such as Express Scripts).

The acquisition process began after ResMed participated in Propeller’s USD $20 Million funding round in May 2018, which also included investment from Aptar Pharma. ResMed, a leader in cloud-connected ventilators for severe Stage III and IV COPD patients, recognized that Propeller’s early-intervention platforms for Stage II and III patients would allow it to support patients earlier in their disease progression.

A key aspect of this transaction was preserving ecosystem neutrality. If Propeller had been acquired by a pharmaceutical manufacturer, competing drug developers would have withdrawn their integrations.

Because ResMed was a medical device manufacturer, it was viewed as a neutral partner by pharmaceutical developers. Post-acquisition, Propeller continued to operate as a standalone business unit, allowing it to maintain its pharmaceutical partnerships while leveraging ResMed's commercial infrastructure in over 120 countries.

This strategy was demonstrated shortly after the acquisition closed, when Propeller launched its "My Pharmacy" integration with Walgreens, allowing patients to manage refills directly within the Propeller app.

Case Study 4: Aptar Group and Voluntis (USA and Europe)

In September 2021, global drug delivery and material science provider Aptar Group acquired a majority stake in French digital therapeutics (DTx) pioneer Voluntis.

Structuring the Cross-Border Transaction

Aptar entered exclusive negotiations to acquire 64.6% of Voluntis’s share capital from management and founding shareholders at a price of €8.70 per share, representing an aggregate valuation of approximately USD $95 Million.

Following clearance from the French Ministry of Economy under foreign investment regulations, Aptar completed the initial block purchase. It then launched a mandatory cash tender offer with the French Markets Authority (AMF) for the remaining outstanding shares at the same price, ultimately executing a squeeze-out to secure 100% ownership by the end of 2021.

Voluntis had developed Theraxium, an algorithmic platform for creating mobile and cloud-based applications to manage chronic conditions. Its portfolio included Insulia (a CE-marked and FDA-cleared titration app for Type 2 diabetes partnered with Sanofi and Biocon) and Oleena (an oncology symptom-management platform approved in the US and Europe).

To value Voluntis’s technology assets during due diligence, Aptar’s valuation teams utilized the Multi-Period Excess Earnings Method (MPEEM), valuing the acquired technology intangible assets at USD 27.9 million and other intangible assets at USD $8.4 Million. This methodology calculated the present value of the future cash flows directly attributable to the Theraxium software platform.

By merging Voluntis’s digital therapeutics platform with its physical drug delivery systems, Aptar created an integrated digital health division capable of offering global pharmaceutical developers unified therapeutic packages.

Anti-Trust, Exclusivity and the Pre-M&A Due Diligence Framework

Using a commercial partnership as a pre-M&A validation tool requires a structured due diligence framework to identify regulatory, financial and legal risks before a transaction is finalised.

Regulatory and Privacy Compliance

During the partnership phase, corporate acquirers must conduct thorough technical audits of the target’s regulatory and compliance frameworks. Due diligence teams must assess the target’s policies and historical data handling across key standards:

Data Privacy: Confirm compliance with US HIPAA regulations and European GDPR requirements, reviewing historical data breaches, user consent records, and data-sharing agreements.
Information Security: Audit the target's engineering standards against SOC 2, ISO 27001, and PCI DSS requirements to identify potential cyber vulnerabilities.
Medical Device Regulation: For software-as-a-medical-device (SaMD) or connected hardware, audit compliance with US FDA premarket notifications and European MDR post-market surveillance and adverse event reporting systems.

Managing Legal Exclusivity and Optionality

While commercial partners often seek long-term exclusive distribution rights, targets should negotiate these clauses carefully. Extended exclusivity periods or aggressive Right of First Refusal (ROFR) clauses can reduce a target’s market valuation by deterring other strategic buyers from bidding.

If exclusivity is required to secure the partnership, targets should limit these periods to 30 to 90 days, tie them to clear performance milestones, and include clear exit clauses if the partner fails to meet agreed sales targets.

Strategic Playbook Conclusions and Recommendations

For venture-backed HealthTech founders and corporate development teams, the partnership-to-M&A pathway offers a reliable mechanism to scale solutions and execute strategic exits.

Recommendations for HealthTech Founders

Validate Product-Market Fit First: Avoid launching complex channel partnerships too early. Ensure your product has demonstrated clear product-market fit and a repeatable direct-sales motion before committing resources to partner enablement.
Focus on Real-World Evidence: Establish commercial pilots that collect concrete clinical and financial data.Demonstrating that your software improves clinical outcomes (such as reducing HbA1c or hospital readmissions) provides strong support for a premium valuation during an acquisition.
Build for Integration: Utilize open, scalable API architectures and data standards. Ensuring your software can integrate into open analytics platforms makes your technology highly attractive to strategic buyers looking for modular, plug-and-play acquisitions.
Protect Corporate Optionality: Avoid signing long-term exclusive distribution agreements or broad ROFRs early in a partnership. Keep your cap table and commercial agreements free of restrictive clauses to ensure a competitive bidding environment during an exit process.

Recommendations for Corporate Acquirers

Use Partnerships as Diligence: Implement a phased acquisition funnel. Leverage minority venture investments and commercial co-selling agreements to evaluate a target’s technology, operational scalability, and team culture before committing to a full acquisition.
Preserve the Target’s Autonomy: When acquiring highly digital, consumer-facing assets, avoid immediately merging them into legacy physical hardware divisions. Maintaining the target’s brand identity, open platform architecture, and separate legal status helps protect its agile development culture and partner ecosystem.
Perform Rigorous Data Audits: Conduct exhaustive pre-acquisition due diligence on the target’s data privacy practices and regulatory filings. Verifying compliance with GDPR, HIPAA, and medical device standards (FDA, EU MDR) protects the parent organization from post-acquisition liability and integration delays.
Structure Balanced Incentives: Ensure that pre-M&A commercial agreements are financially balanced. Use structured revenue-sharing or milestone-based commission models to keep both parties motivated to drive growth and operational alignment.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech